← Back to Clinical Trials
Recruiting NCT05479461

NCT05479461 Technology-enabled Management Versus Usual Care for Blood Pressure

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05479461
Status Recruiting
Phase
Sponsor Stanford University
Condition Hypertension
Study Type INTERVENTIONAL
Enrollment 200 participants
Start Date 2023-06-13
Primary Completion 2025-09-15

Eligibility & Interventions

Sex All sexes
Min Age 30 Years
Max Age 90 Years
Study Type INTERVENTIONAL
Interventions
Digital Hypertension Management SystemUsual Care

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 200 participants in total. It began in 2023-06-13 with a primary completion date of 2025-09-15.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Two arm parallel randomized clinical trial

Eligibility Criteria

Inclusion Criteria: * Age 30-90 yrs. * Smartphone ownership * Office SBP: ≥ 140 mm Hg * ≤ 2 current anti-HTN meds * Able to add or dose-increase at least 2 of the following classes of medications: ACE-I/ARB, diuretic, calcium channel blocker, beta-blocker, mineralocorticoid receptor antagonists (i.e., at least 2 classes are available for addition or dose- increases after excluding intolerant medications and medications currently at maximum dose) * English or Spanish-speakers Exclusion Criteria: * Heart failure with reduced ejection fraction (EF \< 40%) * ESRD (GFR \<15) * Renal replacement therapy * Pregnant * Myocardial infarction or stroke within preceding 6 months * Hospitalization for hypertensive emergency or malignant hypertension within preceding 6 months * Prior solid organ transplantation * At the clinical discretion of the investigators * Enrolled in another clinical study

Contact & Investigator

Central Contact

Paul J Wang, MD

✉ pjwang@stanford.edu

📞 (650) 723-9363

Principal Investigator

Paul J Wang, MD

PRINCIPAL INVESTIGATOR

Stanford University

Frequently Asked Questions

Who can join the NCT05479461 clinical trial?

This trial is open to participants of all sexes, aged 30 Years or older, up to 90 Years, studying Hypertension. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05479461 currently recruiting?

Yes, NCT05479461 is actively recruiting participants. Contact the research team at pjwang@stanford.edu for enrollment information.

Where is the NCT05479461 trial being conducted?

This trial is being conducted at Palo Alto, United States, Atlanta, United States, Eatonton, United States.

Who is sponsoring the NCT05479461 clinical trial?

NCT05479461 is sponsored by Stanford University. The principal investigator is Paul J Wang, MD at Stanford University. The trial plans to enroll 200 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology